Zobrazeno 1 - 10
of 73
pro vyhledávání: '"Neil Singla"'
Autor:
Harold Minkowitz, Hernan Salazar, David Leiman, Daneshvari Solanki, Lucy Lu, Scott Reines, Michael Ryan, Mark Harnett, Neil Singla
Publikováno v:
Drugs in R&D, Vol 20, Iss 3, Pp 225-236 (2020)
Abstract Background and Objective Oral tramadol, an atypical opioid approved in the United States (US) since 1995 and a Schedule IV controlled substance, has less abuse liability compared to Schedule II conventional opioids. Intravenous (IV) tramadol
Externí odkaz:
https://doaj.org/article/c56bd93c3d8c485392b8778f0109b340
Autor:
Neil Singla, MD, Matthew Bindewald, MD, Sonia Singla, DO, David Leiman, MD, Harold Minkowitz, MD, Stewart W. McCallum, MD, Randall J. Mack, BS, Rosemary Keller, PhD, CRNP, Alex Freyer, PharmD, Wei Du, PhD
Publikováno v:
Plastic and Reconstructive Surgery, Global Open, Vol 6, Iss 6, p e1846 (2018)
Background:. A nanocrystal intravenous (IV) formulation of meloxicam is being studied with the aim of providing postoperative analgesia. Methods:. This randomized, multicenter, double-blind, placebo-controlled trial evaluated meloxicam IV 30 mg or pl
Externí odkaz:
https://doaj.org/article/5df992a1935b46138678c83cfeb09ac4
Publikováno v:
Pain
A single dose of DFN-15 up to 250 mg, a celecoxib oral solution, effectively treated moderate to severe pain after a dental surgery.
The analgesic efficacy and safety of DFN-15, a new oral liquid formulation of celecoxib with more rapid absorpti
The analgesic efficacy and safety of DFN-15, a new oral liquid formulation of celecoxib with more rapid absorpti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a52a3ba95d6e0f47ce8bfcb6f5ffde3f
https://doi.org/10.1097/j.pain.0000000000002312
https://doi.org/10.1097/j.pain.0000000000002312
Autor:
Alina C Beaton, Daneshvari Solanki, Hernan Salazar, Steve Folkerth, Neil Singla, Harold S Minkowitz, David Leiman, Ben Vaughn, Nina Skuban, Gwendolyn Niebler
Publikováno v:
Regional Anesthesia & Pain Medicine. :rapm-2022
IntroductionSurgical site infiltration with bupivacaine hydrochloride (HCl) is a standard element of postoperative analgesia for soft tissue surgeries, but results in short-lived analgesia. A novel bupivacaine implant, XARACOLL (bupivacaine HCl), is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fe0271e42eb328a72dd7039581e3c157
https://doi.org/10.1136/rapm-2022-104110
https://doi.org/10.1136/rapm-2022-104110
Publikováno v:
Surgery. 168:915-920
Background Most severe pain occurs within the first 72 hours after an operation, and current local anesthetics have a limited duration of action. HTX-011 is a dual-acting, local anesthetic containing bupivacaine, and low-dose meloxicam in an extended
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ceaca17546ff06822cd37b0e807bfb59
https://doi.org/10.1016/j.surg.2020.06.036
https://doi.org/10.1016/j.surg.2020.06.036
Autor:
Dean Juge, Kushang V. Patel, Tina Tockarshewsky, Eric Devine, Lee S. Simon, John T. Farrar, Geertrui F. Vanhove, Michael P. McDermott, Michael C. Rowbotham, Richard Rauck, Dennis C. Turk, James N. Campbell, Ajay D. Wasan, Philip G. Conaghan, G. Niebler, Mark P. Jensen, Bernard Vrijens, Mittie K. Doyle, David J. Hewitt, Jennifer S. Gewandter, Neil Singla, Daniel B. Carr, Ernest A. Kopecky, Vladimir Skljarevski, Andrew S.C. Rice, Scott R. Evans, Robert D. Kerns, James Witter, Amy A. Kirkwood, Roy Freeman, Richard Malamut, Ian Gilron, Robert H. Dworkin, Nathaniel P. Katz, Penney Cowan, Robert R. Edwards, Nelson E. Sessler, Laurie B. Burke, John D. Markman
Publikováno v:
J Pain
The estimated probability of progressing from phase 3 analgesic clinical trials to regulatory approval is approximately 57%, suggesting that a considerable number of treatments with phase 2 trial results deemed sufficiently successful to progress to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20f3373902b7f2101edd375a389a5c52
https://doi.org/10.1016/j.jpain.2019.12.003
https://doi.org/10.1016/j.jpain.2019.12.003
Autor:
Neil Singla, Scott A Reines, David A. Leiman, Mark Harnett, Michael Ryan, Lucy Lu, Harold S. Minkowitz
Publikováno v:
Journal of Pain Research
Purpose There is a need to reduce exposure to Schedule II opioids in the United States (US) due to the ongoing opioid epidemic. Schedule II opioids have higher potential for abuse and misuse than Schedule IV opioids. This Phase 3, multicenter, single
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b0ed6d3e5d71a14fd49ed32129c7dba
https://doi.org/10.2147/jpr.s251175
https://doi.org/10.2147/jpr.s251175
Autor:
Mark Harnett, Michael Ryan, Harold S. Minkowitz, Daneshvari Solanki, Hernan Salazar, Neil Singla, Lucy Lu, David A. Leiman, Scott A Reines
Publikováno v:
Drugs in R&D, Vol 20, Iss 3, Pp 225-236 (2020)
Drugs in R&D
Drugs in R&D
Background and Objective Oral tramadol, an atypical opioid approved in the United States (US) since 1995 and a Schedule IV controlled substance, has less abuse liability compared to Schedule II conventional opioids. Intravenous (IV) tramadol is not a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01de97d4be775d2d67bf75e7a97eb08c
https://doaj.org/article/c56bd93c3d8c485392b8778f0109b340
https://doaj.org/article/c56bd93c3d8c485392b8778f0109b340
Publikováno v:
British Journal of Anaesthesia. 123:378-391
Summary Respiratory depression is common in patients recovering from surgery and anaesthesia. Failure to recognise and lack of timely institution of intervention can lead to catastrophic cardiorespiratory arrest, anoxic brain injury, and mortality. O
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba0cda6a6e290e5cac09a9bb919fab4f
https://doi.org/10.1016/j.bja.2019.05.044
https://doi.org/10.1016/j.bja.2019.05.044
Publikováno v:
Hernia
Purpose Currently available local anesthetics have not demonstrated sufficient analgesia beyond 12–24 h postoperatively. The purpose of the study was to assess the safety and efficacy of HTX-011 (bupivacaine and meloxicam in Biochronomer® polymer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5cabf337a7974bbfaf2684e46b5d3fcc
https://doi.org/10.1007/s10029-019-02023-6
https://doi.org/10.1007/s10029-019-02023-6